Immunome shares surge 12.76% after-hours as Truist and Goldman Sachs initiate Buy ratings with $36 and $26 price targets.

Immunome Inc. (IMNM) surged 12.76% in after-hours trading, driven by multiple catalysts. The stock reached a 52-week high of $19.16, fueled by the initiation of Buy ratings from Truist Securities ($36 price target) and Goldman Sachs ($26 price target), citing varegacestat’s potential for desmoid tumors. Additionally, a research collaboration with Infinimmune and positive preclinical data on its ADC HC74 highlighted Immunome’s R&D progress. While technical factors and options activity (e.g., $20 call options with 9,072 turnover) amplified the 13.4% intraday rally, the fundamental news—analyst upgrades and pipeline advancements—were the primary drivers. The stock’s robust performance reflects growing investor confidence in its long-term prospects, despite being slightly above fair value estimates.